AVBP – arrivent biopharma, inc. (US:NASDAQ)
Stock Stats
News
ArriVent BioPharma: A De-Risked Binary With Near-Term Catalysts [Seeking Alpha]
ArriVent BioPharma (NASDAQ:AVBP) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer [Yahoo! Finance]
ArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung Cancer
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: Octagon Capital Advisors LP
Form 10-Q ArriVent BioPharma, Inc. For: Sep 30
Form 8-K ArriVent BioPharma, Inc. For: Nov 10
Form SCHEDULE 13G/A ArriVent BioPharma, Inc. Filed by: FMR LLC
Form SCHEDULE 13G ArriVent BioPharma, Inc. Filed by: VANGUARD GROUP INC
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.